Novo and Orbis Sign 1.4 Billion Dollar Deal
Orbis Medicines and Novo Nordisk formed a partnership worth up to 1.4 billion dollars to develop oral therapies for cardiometabolic diseases. The collaboration utilizes Orbis artificial intelligence platform to create novel macrocycle drugs.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B partnered with Orbis Medicines on Thursday afternoon in a discovery deal worth up to $1.4 billion for oral cardiometabolic therapies. The collaboration targets a shift from traditional injectables to swallowed macrocycle drugs. The agreement includes upfront fees, milestone payments, and tiered sales royalties for Orbis alongside a strategic equity investment from the Denmark drugmaker.
